Looking for a B(eefy) exit

Investors are hoping last week's $43 million series B round for NeuroTherapeutics Pharma Inc. will get the biotech all the way to an acquisition.

Heath Lukatch, partner at Novo Ventures and chairman of NeuroTherapeutics, told Ebb & Flow that the round should get the company through three years and "three robust Phase IIa trials in pain and epilepsy" for preclinical lead candidate NTP-2014...